期刊
LANCET NEUROLOGY
卷 15, 期 1, 页码 78-91出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(15)00298-7
关键词
-
资金
- National Institute for Health Research Clinician Scientist Fellowship [NIHR-CS-011-028]
- Medical Research Council, UK [MR/K015184/1]
- MRC [G0601430, MR/K015184/1] Funding Source: UKRI
- Medical Research Council [G0601430, MR/K015184/1] Funding Source: researchfish
- National Institute for Health Research [NIHR-CS-011-028, CL-2009-09-001] Funding Source: researchfish
- National Institutes of Health Research (NIHR) [NIHR-CS-011-028] Funding Source: National Institutes of Health Research (NIHR)
Idiopathic intracranial hypertension is a disorder characterised by raised intracranial pressure that predominantly affects young, obese women. Pathogenesis has not been fully elucidated, but several causal factors have been proposed. Symptoms can include headaches, visual loss, pulsatile tinnitus, and back and neck pain, but the clinical presentation is highly variable. Although few studies have been done to support evidence-based management, several recent advances have the potential to enhance understanding of the causes of the disease and to guide treatment decisions. Investigators of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) reported beneficial effects of acetazolamide in patients with mild visual loss. Studies have also established weight loss as an effective disease-modifying treatment, and further clinical trials to investigate new treatments are underway. The incidence of idiopathic intracranial hypertension is expected to increase as rates of obesity increase; efforts to reduce diagnostic delays and identify new, effective approaches to treatment will be key to meeting the needs of a growing number of patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据